Bayer Healthcare, a US subsidiary of the German Bayer group, and partner Onyx have halted a late-stage clinical trial of their Nexavar (soragenib) in patients with non-small cell lung cancer, after the independent monitoring board concluded that it would not meet its primary endpoint of improved overall survival.
The news saw Bayer's share price drop 2.3% to 54.40 euros by close of February 18, the day of the announcement.
The Phase III ESCAPE trial evaluated Nexavar administered in combination with the chemotherapeutic agents carboplatin and paclitaxel in patients with NSCLC. Safety events were generally consistent with those previously reported. However, higher mortality was observed in the subset of patients with squamous cell carcinoma of the lung treated with sorafenib and carboplatin and paclitaxel versus those treated with carboplatin and paclitaxel alone, the firms noted.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze